Literature DB >> 8714863

HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy.

E Yoles1, M Belkin, M Schwartz.   

Abstract

HU-211 is a novel synthetic analog of tetrahydrocannabinol that was recently shown in animal models to be nonpsychotropic. In this study we show that HU-211 can potentially be used as a neuroprotective compound in the CNS. Using a calibrated crush injury of adult rat optic nerve, we show that HU-211 can reduce injury-induced metabolic and electrophysiological deficits. Energy metabolism was monitored by measuring the intramitochondrial nicotine-amine adenine dinucleotide redox state hourly for 6 h after injury and treatment. Electrophysiological activity was assessed by compound action potential and visual evoked potential response. Beneficial effects were dose-dependent, being optimal at 7 mg/kg, administered intraperitoneally. The time window during which treatment was effective was found to be from the time of injury for at least 5 h, with treatment most effective at the time of injury. These results strongly suggest that HU-211, given immediately after CNS injury at the optimal dosage, may possess neuroprotective activities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8714863     DOI: 10.1089/neu.1996.13.49

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  11 in total

1.  Protective autoimmunity is a physiological response to CNS trauma.

Authors:  E Yoles; E Hauben; O Palgi; E Agranov; A Gothilf; A Cohen; V Kuchroo; I R Cohen; H Weiner; M Schwartz
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.

Authors:  Azza B El-Remessy; Ibrahim E Khalil; Suraporn Matragoon; Gamal Abou-Mohamed; Nai-Jer Tsai; Penny Roon; Ruth B Caldwell; Robert W Caldwell; Keith Green; Gregory I Liou
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 4.  Cannabinoids and glaucoma.

Authors:  I Tomida; R G Pertwee; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

Review 5.  Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature.

Authors:  Shaun E Gruenbaum; Alexander Zlotnik; Benjamin F Gruenbaum; Denise Hersey; Federico Bilotta
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

6.  Molecular reorganization of endocannabinoid signalling in Alzheimer's disease.

Authors:  Jan Mulder; Misha Zilberter; Susana J Pasquaré; Alán Alpár; Gunnar Schulte; Samira G Ferreira; Attila Köfalvi; Ana M Martín-Moreno; Erik Keimpema; Heikki Tanila; Masahiko Watanabe; Ken Mackie; Tibor Hortobágyi; Maria L de Ceballos; Tibor Harkany
Journal:  Brain       Date:  2011-04       Impact factor: 13.501

Review 7.  Use of Medical Cannabis to Treat Traumatic Brain Injury.

Authors:  Danielle C Hergert; Cidney Robertson-Benta; Veronik Sicard; Daniela Schwotzer; Kent Hutchison; Dan P Covey; Davin K Quinn; Joseph R Sadek; Jacob McDonald; Andrew R Mayer
Journal:  J Neurotrauma       Date:  2021-01-25       Impact factor: 4.869

Review 8.  Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Michihiro Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-08

Review 9.  Neuroprotection in Glaucoma.

Authors:  Azadeh Doozandeh; Shahin Yazdani
Journal:  J Ophthalmic Vis Res       Date:  2016 Apr-Jun

Review 10.  Novel Therapeutics in Glaucoma Management.

Authors:  Claudio Bucolo; Chiara Bianca Maria Platania; Filippo Drago; Vincenza Bonfiglio; Michele Reibaldi; Teresio Avitabile; Maurizio Uva
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.